



## A NARRATIVE STUDY ABOUT THE ROLE OF QURS ZARISHK AS UNANI FORMULATION IN MANAGEMENT OF HEPATIC INSUFFICIENCY AND ANEMIA WITH HYPOPROTEINAEMIA

**Khalid Ali Khan<sup>1\*</sup> Rashid Ali Khan<sup>2</sup>, Mohammad Zakir<sup>3</sup> & Mohd Noman Taha<sup>4</sup>**

<sup>\*1</sup>Department of Ilmul Jarahat (Unani Surgery), University College of Unani, Tonk, Rajasthan, India.

<sup>2</sup>Department of Amraz-e-Jild wa Zohrawiya wa Tazeeniyat (Unani Dermatology, Cosmetology & Venerology), University College of Unani, Tonk, Rajasthan, India.

<sup>3-4</sup>Department of Ilmul Advia (Pharmacology), National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad-500038 (Telangana), India.

**\*Corresponding Author:**

**Khalid Ali Khan,**

Email: [bargi786@gmail.com](mailto:bargi786@gmail.com)

### Abstract:

Diseases of the liver are common now due to various reasons including the use of junk food, adulteration of food items, sedentary and stressful life, etc. The liver is the main organ for the digestion of various food items and also produces various enzymes and hormones. The insufficiency of the liver and anemia with hypoproteinemia is a life-threatening condition and the cause lies in the liver. In modern medicine, there is no cure for these conditions and only supportive and supplement therapy is used to support the liver and to increase life expectancy. The supplement therapy is costly, needs repetitions, and may also cause side effects. In the Unani system of Medicine (USM), several drugs are available and used for liver diseases with success for centuries. Qurs Zarishk is a tablet form of compound formulation specifically used for liver insufficiency and anemia with hypoproteinemia in USM. This formulation has been used for centuries for its indications with success. This review aims to explore its therapeutic activity and uses on the basis of experimental studies on QZ as well as its ingredients to understand its indication.



All the articles published by Chelonian Conservation and Biology are licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](https://creativecommons.org/licenses/by-nc/4.0/) Based on a work at <https://www.acgpublishing.com/>

**Keywords:** Anemia with hypoproteinemia, liver insufficiency, Hepatoprotective, Qurs Zarishk, Zarishk, Unani.

## 1. Introduction:

Hepatic insufficiency, also known as liver insufficiency or liver failure, is a condition in which the liver is unable to function properly or adequately perform its essential metabolic, synthetic, and detoxification functions. The liver plays a crucial role in various physiological processes, and when it fails to function adequately, it can lead to serious health consequences. The symptoms of hepatic insufficiency can vary depending on the severity and the underlying cause but may include, jaundice, fatigue and weakness, edema, nausea and vomiting, ascites, itchy skin, and dark urine and pale stools (1).

Hypoproteinaemia is a common clinical indicator of liver cirrhosis. The protein synthesis and coagulating factors in liver is insufficient due to decline in number and function of the liver cells in liver cirrhosis (2). Hypoproteinaemia accelerates the hepatic insufficiency, decrease immunity, increases chances of infection, ascites and decrease in functions of the organs leading to sluggish prognosis and increased fatality rate. At present, the management of hypoproteinaemia is a challenge for many hepatologists. However, many problems like shortage of blood product resources, specific nutritional supplements, blood transfusion reaction hinders the effective management of hypoproteinaemia. Therefore, any alternative treatments are urgently needed to manage the anemia with hypoproteinaemia (AHP) (3).

The Unani System of Medicines (USM) have rich source of natural drugs available for various diseases of liver including liver insufficiency, liver cirrhosis, anemia with hypoproteinaemia (AHP) and other diseases of the liver. *Qurs Zarishk* (QZ) is an herbal formulation commonly used for its various health benefits. It is primarily composed of *Zarishk* (*Berberis aristata* D.C), which is the main ingredient and gives the formulation its name. QZ is known for its antimicrobial, anti-inflammatory, diuretic and antioxidant properties. It is often used in USM to treat liver problems, AHP, digestive disorders, and skin conditions. It is believed to have a cooling effect on the body and is used to balance the excess heat or *Khilt-i-Safra'* (bilious humour) in the body. The specific uses of QZ can vary depending on the individual and the practitioner's diagnosis. It is commonly used to alleviate symptoms such as jaundice, AHP, indigestion, diarrhea, abdominal pain, and skin rashes. Additionally, it may be used to support liver function and promote overall detoxification (4).

This review is proposed to explore the possible role of QZ in the management of liver insufficiency and AHP. The therapeutic actions and uses of the QZ will be explored with the help of various preclinical and other studies done on its ingredients along with their traditional uses.

## 2. Methodology

The information on QZ was extracted from using a variety of accessible bibliographic databases, electronic resources (PubMed, Science Direct, Springer, and Google Scholars), and classical literature from traditional books, by key word of Qurs Zarishk, Zarishk, Rewand Chini, Gul-e-

Surkh, Maghz-e-Tukhm-e-Khiyarain, Sandal Safaid, Tukhm-e-Kasni, Luk Maghsool, Asl-us-Soos, Gul-e-Nilofar, Tabasheer, and botanical names i.e., *Berberis aristata*, *Rheum emodi*, *Rosa damascena*, *Cucumis sativus*, *Cucumis utilissimus*, *Santalum album*, *Cichorium intybus*, *Coccus lacca*, *Glycyrrhiza glabra*, *Nymphaea alba*, and *Bambusa bambos*; the name of diseases i.e., hepatic insufficiency and AHP. Additionally, offline journals were also searched in the NRIUMSD Hyderabad library including the Hippocratic Journal of Unani Medicine, and Indian Journal of Unani Medicine etc. The detail about the QZ, and its ingredients has been surveyed from different classical books of USM.

### 3. Results and Discussion

According to Unani classics the condition in which an impairment takes place in the *Mizāj* (temperament) and *Quwwat Mughayyira* (transformative faculty) of the liver is called as *Sū'al-Qinya* because it occurs prior to locally or generalized edema of the body. *Sū'al-Qinya* is defined as derangement of the *Mizāj*(temperament) of liver which makes it unable to form normal blood and leads to ascites. The sign and symptoms includes, body colour change, puffiness of the body, weakened digestion, loss of appetite, sleep disturbance, irregular bowels, flatulence, reduced healing process and fatigue. This disease is the result of either hepatic insufficiency or due to other diseases. It is similar to anaemia with hypoproteinaemia (5,6,7).

*Sū'al-Qinya* is combination of two Arabic words 'Sū' and 'Qinya, where "Sū" mean defect and 'Qinya' or 'Quniya' means treasure or precious possession. The term *Sū'al-Qinya*, means defect in the asset of the body respectively since blood is supposed to be the most important asset of the body; therefore *Sū'al-Qinya* is a disorder in which the blood becomes defected. The terms *Faqr al-Dam*, *Qillat al-Dam* and *Fasād al-Dam* are used as synonymous for *Sū'al-Qinya*. It is the condition in which there is decrease in the amount of blood and alteration in its constituents. Also, there is decrease in the number of *Kurayyāt Hamrā'* (red blood corpuscles), *Kurayyāt Baydā'* (white blood corpuscles) and *Safihāt Damwiyya* (platelets) and water is increased(8).

*Ismā'īl Jurjānī*, in his book *Dhakhīra Khawārizm Shāhī*, described that *Sū'al-Qinya* is a condition in which liver becomes functionally weak, leading to alterations in the temperament, deterioration of the whole body, mimicking *Istisqā' Lahmī* (anasarca)(9,10). *Majūsī* (10th AD), in his book *Kāmil-al-Sanā* wrote, disability of blood formation is either due to impairment of the liver, when the digested nutrient of food could not be transferred into blood or any impairment of the stomach. He also said that excessive bleeding is the main cause of reduced blood formation (10). According to *Rabban Tabri* (810-895 AD), liver is the reservoir of blood and if excessive bleeding occurs in menses, the blood supply to the liver decreases and its functions deranges (11).

As Ibn Sina says, physiologically *Quwwat Mughayyira* (transformative faculty) found in the liver performs functions by which the whole body is got benefitted. During metabolism, processes, production of energy and transformed major constituents of blood takes place in the liver. This pattern becomes weak and altered due to chronic inflammatory conditions, fevers, infections, which effect digestive system and four stages of digestion i.e., *Hadm Mi'dī* (first digestion/ alimentary digestion/chyme formation), *Hadm Kabidī* (hepatic digestion/chyle formation), *Hadm*

'*Uruqī* (tertiary digestion/vascular digestion) and *Hadm 'Udwi* (fourth digestion/organic digestion) and leads to insufficiency of blood in the body. Features of this condition like swelling of face, eyelids, upper arms, or whole body, lethargy, pallor, decreased appetite, gingivitis, alternate diarrhea, constipation, disturbed or deep sleep, psychogenic disorders are noticeable. Constant blood loss in diseases like Menorrhagia, bleeding piles are responsible for this condition (7,12).

### 3.1 The Composition of *Qurs Zarishk*(QZ)

QZ is made up of ten ingredients in different concentrations. The main therapeutic actions of the formulation are *Muqawwi-i-Kabid* (hepatotonic), *Muhallil Waram* (resolvent of inflammation) and *Mudirr-i-Bawl* (diuretic) and its therapeutic uses are *Du'f al-Kabid* (hepatic insufficiency) and *Sū'al-Qinya* (anemia with hypoproteinaemia) as per Unani literature. The dose mentioned is 5-10 gm per day. The composition is given in the following table (4).

S. No	Name of the Drug	Scientific Name	Part used	Quantity in gm
1.	Zarishk	<i>Berberis aristata</i> D.C	Fruits	8 parts
2.	Rewand Chini	<i>Rheum emodi</i> Wall.	Rhizome	2 parts
3.	Gul-e-Surkh	<i>Rosa damascena</i> Mill.	Flower	2 parts
4.	Maghz-e-Tukhm-e-Khiyarain	<i>Cucumis sativus</i> L. & <i>Cucumis utilissimus</i> Roxb.	Seeds kernel	2 parts
5.	Sandal Safaid	<i>Santalum album</i> L.	Wood powder	2 parts
6.	Tukhm-e-Kasni	<i>Cichorium intybus</i> L.	Seeds	2 parts
7.	Luk Maghsool	<i>Coccus lacca</i>	Resinous secretion	1 part
8.	Asl-us-Soos	<i>Glycyrrhiza glabra</i> L.	Root	1 part
9.	Gul-e-Nilofar	<i>Nymphaea alba</i> L.	Flower	1 part
10.	Tabasheer	<i>Bambusa bambos</i> (L.) Voss.	Bamboo Manna	1 part

### 3.2 The medicinal properties of the ingredients of QZ.

#### 3.2.1 ZARISHK (*Berberis aristata* D.C)

It is commonly known as Indian Barberry or Daruharidra. It is a fruit of a thorny plant which is smaller than the Kishmish (dry fruit of *Vitis vinifera* L.), reddish black and sour in taste. The dry extract of the wood of the plant *Berberis aristata* is known as Rasot in USM and used for the management of various diseases (13-14).

The *Mizāj* (temperament) of Zarishk is *Bārid Yābis* (Cold&dry) in second degree. Its *Miqdar-i Khurak* (dose) is 3-5 gm. Zarishk is harmful for the people having *Balghami al-Mizāj* (phlegmatic temperament). *Muslih* (corrective) is used to reduce adverse effects/side effects or improve the drug's efficacy. Shakkar (sugar) and Qaranfal (*Eugenia caryophyllus* Bull.) may be used as a

corrective to neutralize the side effects of Zarishk. The *Badal* (substitute) of Zarishk are Zār-e-ward (*Rosa damascena* Mill.) and Sandal Safaid (*Santalum album* L.), the substitute has been used if the original drug is not available due to various reasons.(15-18)

### 3.2.1.1 Therapeutic actions and uses of Zarishk:

It is known for its actions e.g., *Muqawwi-i-Jigar* (hepatotonic), *Musakkin-i Safra* (neutralizing the heat of yellow bile), *Musakkin-i-Harārat Mida & Jigar* (neutralize the excessive heat in stomach and liver), *Musakkin-i Dam* (neutralizing the heat of blood), *Muqawwi-i-Qalb*(cardiotonic), *Muqawwi-i-Mi'da*(stomachic), *Musakkin-i-Atash* (neutralize the thirst), and *Qabid* (astringent). It is used to manage *Salaba al-Kabid* (cirrhosis of liver), *Humma Safrawwiya*(fever due to bile), *Ghasiyan* (nausea), *Qay'* (vomiting), *Ishal Safrawi* (purgation due to bile),and useful in all *Safrawi Amraz* (diseases due to derangement of bile) (15-18).

### 3.2.1.3 Pharmacological properties of *Berberis aristata* D.C:

Various studies have proved the following activities of the Zarishk e.g., Hepatoprotective (19-21), Antidiarrheal (22-23), Anti-PAF (platelet activating factor) activity (24),Cardiotonic (25-26), Antidiabetic (27-29), Anticancer (30-32), Anti-inflammatory (33), Antimicrobial (34-35), Antidepressant (36-37).

### 3.2.2 REWAND CHINI(*Rheum emodi* Wall.)

It is also known as Rhubarb, Himalayan Rhubarb. It is common in Sub-alpine Himalayas, from Kashmir to Sikkim at altitudes of 3300-5200 meter and also cultivated in Assam. Rhein,emodin, chrysophanol,emodin-3-monomethyl ether, aloe-emodin found in the root. The gallic acid and small amount of tannin, cinnamic and rheinolic acids, volatile oil, starch and calcium oxalate were also present in the root. Glycoside, Sennoside A and B, along with free anthraquinones also found (13-14).

The *Mizāj* (temperament) of Rewand Chini (*Rheum emodi* Wall.) is *Murakkabul Quwa* (different temperament), means it has two types of temperament which affects their action at different time and at different doses. The *Miqdar-i Khurak* (dose) of Rewand Chini is 1.5-2 gm for purgation and 125 mg to 375 mg to produce constipation. The Rewand Chini should not be used for purgation in weak person. Samagh Arabi (*Acacia Arabica* Willd.), Kateera (*Cochlospermum religiosum* L.), and Luab Behidana (*Cydonia oblonga* Mill.) may be used as a corrective to neutralize the side effects. Its *Badal* (substitute) is Gule surkh (*Rosa damascena* Mill.) in case it this drug is not available(15-18).

### 3.2.2.1 Therapeutic actions and uses of Rewand Chini:

Its actions are *Muharrrik-i-Jigar* (liver stimulant), *Muqawwi-i-Mi'da* (stomachic), *Muqawwi-i-Badan* (immunity booster) in low dose, *Munaffith-i-Balgham* (expectorant), and *Qabid* (astringent). It is used in *Yaraqan Asfar* (jaundice), *Istisqa'* (ascites), *Waram al-Kabid*

(hepatitis) and *Waram al- Tihal* (splenitis), *Su'al-o-Surfa* (cough/bronchitis), *Zu'f al-Am'a'* (enteropathy), *Zu'f al-Mida* (weakness of stomach), *Nafkh-e Shikam* (flatulence) (15-18).

### 3.2.2.3 Pharmacological properties:

Various studies have proved the following activities of the Rewand Chini e.g., Cathartic (38-39), Anticancer (40), Hepatoprotective (41), Anti-inflammatory (42), Diabetic nephropathy (43), and Analgesic (44).

### 3.2.3 GUL-E-SURKH (*Rosa damascena* Mill.)

It is cultivated chiefly in central Uttar Pradesh and grown as decorative plant in gardens all over India. The kaempferol, quercetin, and cyanidin has been found in all parts of the plant. The hip yields zeaxanthin, rubixanthin, lycopene, taraxanthin and xanthophyll. An essential oil has been extracted from the flowers which contain geraniol citronellol, beta-phenylethanol, nerol, eugenol and methyl eugenol; also contains tannin, organic acids, cyanin, chlorogenic acid, cyanidin and its 3,5-diglucoside, carotene, quercitrin, and sugars. The chlorogenic acid, carotene, and sugars has been isolated from pollen (13-14).

*The Mijāz* (temperament) of Gul-e-Surkh is *Murakkabul Quwa* (different temperament) means it has two types of temperament which exerts their action at different time and at different doses. The *Miqdar-i Khurak* (dose) is 5-7 gm. Gul-e-Surkh is harmful for *Quwwat-e-Bāh* (libido). Anisoon (*Pimpinella anisum* L.), and Habbul Zalam (*Cyperus esculentus* L.) may be used to reduce or neutralize the side effects. Its *Badal* (substitute) are Banafsha (*Viola odorata* L.) and Marzanjosh (*Origanum vulgare* L.) (15-18).

#### 3.2.3.1 Therapeutic actions and uses of Gul-e-Surkh:

It is known for its actions like *Mufarrih wa Muqawwi-i-A'da' Ra'isa* (tonic for vital organs), *Muqawwi-i-Badan* (Immunity booster), *Musakkin-i Safra* (neutralizing the heat of yellow bile), *Muqawwi-i -Mi'da* (Stomachic), *Muqawwi-i-Dimagh* (Brain tonic), *Muqawwi-i-Qalb* (Cardio tonic), *Musakkin-i Balgham* (neutralizing the heat of phlegm), *Muhallil Waram* (resolvent of inflammation) and *Muhallil-i Riyah* (carminative). It is used to manage *Zu'f al-Kabid* (hepatic insufficiency), *Zu'f al-Am'a'* (enteropathy), *Zu'f al-Mida* (weakness of stomach), *Khafaqan* (palpitation), *Ghashi* (syncope), *Zu'f al-Qalb* (cardiac insufficiency), *Nafth al-Dam* (hemoptysis), *Hummā* (fever), *Ghashi* (syncope), *Sudā'* (headache) (15-18).

#### 3.2.3.3 Pharmacological properties:

Various studies have proved the following activities of the Gul-e-Surkh e.g., Antimicrobial (45-46), Antiviral (47) Anti-inflammatory (48), Antioxidant (49), Anticancer (50), Neuroprotective (51), Antidiabetic (52).

### 3.2.4 MAGHZ-E-TUKHM-E-KHIYARAIN (*Cucumis sativus* L. and *Cucumis utilissimus* Roxb.)

The fruits of *Cucumis sativus* L. is used as salad vegetable and cultivated for this reason. Rutin, cucurbitaside (glucosides), cucurbitasides B & C, alpha-spinasterol and ferredoxin have been isolated from it. The seedlings contain sterols in male and female flowers. The ascorbic acid oxidase, proteolytic enzymes, succinic and malic dehydrogenases has also been reported. The *Cucumis utilissimus* Roxb is cultivated in western Uttar Pradesh and Punjab (13-14).

The *Mizāj* (temperament) of Maghz-e-Tukhm-e-Khiyarain is *Bārid Ratb* (Cold & Moist) in second degree. Its *Miqdar-i Khurak* (dose) is 5-7 gm. It is harmful for *Barid Mizāj* (cold temperament peoples). Badiyan (*Foeniculum vulgare* Gaertn.) and Zanjabeel (*Zingiber officinale* Rosc.) may be used to neutralize the side effects (15-18).

### 3.2.4.1 Therapeutic actions and uses of Maghz-e-Tukhm-e-Khiyarain:

Its actions includes *Musakkin-i Safra* (neutralizing the heat of yellow bile), *Musakkin-i Dam* (neutralizing the heat of blood) and *Mudirr-i-Bawl* (diuretic). It is prescribed in *Waram al-Kabid Harr* (hepatitis), *Waram al-Tihal Harr* (splenitis), *Hummiyat Harra* (fever due to *Safra*), *Sozish-i-Mida* (burning sensation in stomach), (15-18).

### 3.2.4.3 Pharmacological properties:

Antioxidant activity (53-54), Antimicrobial (54) antiaging and anti-wrinkle activity (55-56), Antidiabetic (57-58), Hypolipidemic activity (59), Hepatoprotective activity (60) anticancer (61).

### 3.2.5 SANDAL SAFAID (*Santalum album* L.)

Peninsular India from Vindhya mountains southwards, Karnataka and Tamil Nadu are natural habitat of it. Triterpene-*urs-12-en-3* butyl-palmitate has been isolated from the bark. An essential oil is also present in heartwood which contains alpha-santalol, beta-santalol and dihydroagarofuran. The sesquiterpene hydrocarbons-alpha-, beta-, *epi*-beta-santalene and alpha- and beta-curcumene and beta-farnesene was also found (13-14).

The *Mijāz* (temperament) of Sandal Safaid is *Barid Yābis* (Cold & Dry) in second degree. Its *Miqdar-i Khurak* (dose) is 5-7 gm. It is harmful as *Qāti'-i-Bāh* (anaphrodisiac), and Shahad (honey) & Nabat (clarified sugar) may be used to reduce or neutralise its side effects. The Kafoor (*Cinnamomum camphora* Nees & Eberm) and Ushna (*Parmelia perlata* Ach.) may be used as substitute in case of nonavailability of sandal safaid (15-18).

### 3.2.5.1 Therapeutic actions and uses of Sandal Safaid:

The actions of this plants are *Muqawwi-i-Dimagh* (brain tonic), *Mufarrih wa Muqawwi-i-Qalb* (cardio tonic), *Muqawwi-i -Mi'da* (stomachic), and *Musaffi-i-Dam* (blood purifier). It is used for the management of *Waram al-Kabid Harr* (hepatitis), *Zu'f al-Qalb* (cardiac insufficiency), *Khafaqan* (palpitation), and *Hurqa al-Bawl* (burning maturation) (15-18).

### 3.2.5.3 Pharmacological properties:

Antidiabetic (62), Antifungal (63), Antibacterial (64), Antioxidant (65) Anticancer (66).

### 3.2.6 TUKHM-E-KASNI (*Cichorium intybus L.*)

Its natural habitat is Europe and commonly found in North West India, Tamil Nadu and parts of Andhra Pradesh. The root contains 58% inulin, lactucin, lactucopicrin, chicoriin, esculetin, esculin, umbelliferone, scopoletin and glucofructosans. Citric and tartaric acids is found in fresh chicory while acetic, lactic, pyruvic, pyromucic, palmitic and tartaric acids have been found in roasted chicory root<sup>13-14</sup>).

The *Mizāj* (temperament) is *Barid Yābis* (Cold & Moist) in second degree. Its *Miqdar-i Khurak* (dose) is 7-12 gm. It produces nausea and Sikanjabin (a compound formulation prepared by Vinegar and Honey) may be used to neutralize the side effect (15-18).

#### 3.2.6.1 Therapeutic actions and uses of Tukhm-e-Kasni:

The actions of the seeds are *Musakkin-i Safra* (neutralizing the heat of yellow bile), *Musakkin-i Dam* (neutralizing the heat of blood), *Mufattih-i Sudad* (deobstruent), and *Mudirr-i-Bawl* (diuretic). the drug is mentioned in the management of *Istisqa'* (ascites), *Hummayāt Safrawwiya* (fever due to bile), *Yaraqan Suddi* (obstructive jaundice), and *Hummayāt Muzmina* (chronic fever)(15-18).

#### 3.2.6.3 Pharmacological properties:

*Antimicrobial* (67-68), *Anthelmintic* (69-70), *Antimalarial* (71), *Hepatoprotective* (72-73), *Antidiabetic* (74-75), *Gastroprotective* (76), *Anti-inflammatory*, *Analgesic* (77), *Antioxidant* (78), *Tumour inhibitory activity* (79).

### 3.2.7 LUK MAGHSOOL (*Coccus lacca*)

Luk, commonly known as Lac or Lacca, is a resinous secretion produced by the female lac insect (*Laccifer lacca*). This insect is native to Southeast Asia and parts of India. It is produced in Burma, Assam, Madhya Pradesh, Uttar Pradesh, Bihar and Odisha. In USM, *Coccus lacca* has been used for its medicinal properties and is known by the name Luk, Lakh Dana. Luk Maghsool is processed Lac by a special procedure mentioned in the Unani Literature. It is used in both traditional and herbal medicine systems for treating different ailments. Lac contains wax (6%), red colouring matter (6.5%), laccic acid, resin (70-85%) (80).

The *Mizāj* (temperament) is *Hārr Yābis* (Hot<sup>2</sup> & Dry<sup>3</sup>). Its *Miqdar-i Khurak* (dose) is 0.5 to 2 gm. It is harmful in *Amrād al-Tihāl* (diseases of the spleen). *Mastagi* (*Pistacia lenticus L.*) may be used to neutralize the side effects (15-18).

#### 3.2.7.1 Therapeutic actions and uses of Luk Maghsool:

Its therapeutic acts includes *Jali* (Detergent), *Muhallil* (Resolvent), *Munaffith-i-Balgham* (Expectorant), and *Mujaffif* (desiccant). It is used to manage *Istisqa' Ziqqī* (ascites), *Yaraqan Asfar* (jaundice), *Su 'al-o-Surfa* (cough/bronchitis), and *Siman Mufrit* (obesity)(15-18).

#### 3.2.7.3 Pharmacological properties:



Antiobesity effects (81-82), Anti-hyperlipidemic (83), antifertility activity (84).

### 3.2.8 ASL-US-SOOS (*Glycyrrhiza glabra* L.)

Mediterranean region is natural habitat of *Glycyrrhiza glabra*. It is grown in Now grown in Jammu and Kashmir, Punjab, and South India. The glycyrrhizin is the main chemical constituent, other constituents include glycyrrhetic (glycyrrhetic) acid, chalcones, isoflavonoids, coumarins, triterpenoids and sterols, amines, lignans, amino acids, gums and volatile oils<sup>13-14</sup>).

The *Mijāz* (temperament) of Asl-us-Soos is *Murakkabul Quwa* (different temperament), means it has two types of temperament which exerts their action at different time and at different doses. Its *Miqdar-i Khurak* (dose) is 3-5 gm. It is harmful for Tihāl (spleen) and Kulya (kidneys). For spleen Kateera (gum of *Cochlospermum religiosum* L.) and for kidney Gule Surh (flower of *Rosa damascena* Mill.) may be used as corrective (15-18).

#### 3.2.8.1 Therapeutic actions and uses of Asl-us-Soos:

Its actions are *Mundij* (concoctive), *Muqawwi-i-A'sab* (nervine tonic), *Musakkin* (neutralize the heat of humours), *Mulayyin-i-Waram* (resolvent), *Mulayyin-i-Am'a'* (laxative), and *Mukhrij-i-Balgham* (expectorant). The therapeutic use of this includes *Rabw* (bronchial asthma), *Sual* (cough), *Buhha al-Sawt* (hoarseness of voice), and *Sozak* (gonorrhoea) (15-18).

#### 3.2.8.3 Pharmacological properties:

Antioxidant (85-86), Anti-inflammatory activity (87), Antitussive and expectorant activity (88), Anti-ulcerative activity (89), Antimicrobial activity (90-91), Antiviral activity (91-92), Hepatoprotective activity (93), Anticancer activity (94), Neuroprotective activity (95), Sedative activity, Antidepressant (96).

### 3.2.9 GUL-E-NILOFAR (*Nymphaea alba* L.)

It is native for Kashmir (in lakes). The flavonoids i.e., quercetin, kaempferol, apigenin has been found in flower. It contains a cardiac glucoside, nymphalin, which exerts sedative action in small doses. The petroleum ether extract of the plant of *Nymphaea* species, has shown hepatoprotective effects in CCL<sub>4</sub> induced liver toxicity study in rats (13-14).

The *Mijāz* (temperament) of *Gul-e-Nilofar* is *Barid Ratb* (Cold & Moist) in second degree. The *Miqdar-i Khurak* (dose) is 3-5 gm. It uses produce *Du'f al-Mathana* (weakness of bladder). The Shahad Khalis (honey) may be used to neutralize the side effects (97).

#### 3.2.9.1 Therapeutic actions and uses of Gul-e-Nilofar :

It has actions like *Dafti'-i Hummiyat Safrawwiya* (antipyretic to bilious fever), *Mufarrih wa Muqawwi-i-Qalb* (cardio tonic), *Muqawwi-i-Dimagh* (brain tonic), and *Munawwim* (hypnotic). It is used to manage *Hummayāt Safrawwiya* (fever due to bile), and *Khafaqan* (palpitation) (97).

#### 3.2.9.3 Pharmacological properties:

Antifungal, Antitumor (98), Antioxidant (98-100), Anti Hepatitis-C (101), Hepatoprotective, Anti-inflammatory activity (100-101), and Anti-cancer activity (102).

### 3.2.10 TABASHEER (*Bambusa bambos* (L.) Voss.)

It is Wild throughout India, especially in the hill forests of Western and Southern India. In Unani it is called Qasab, Tabashir (Bamboo manna). The plant gave cyanogenic glucoside taxiphyllin. Bamboo-manna contains silicious crystalline substances (13-14).

The *Mijāz* (temperament) of Tabasheer is *Barid Yābis* (Cold & Moist) in second degree. Its *Miqdar-i Khurak* (dose) is 1-3 gm. It is harmful for *Quwwat-i-Bah* (libido) and *Ri'a* (lungs). Shahad (honey), Mastagi (*Pistacia lenticus* L), Unnab (*Zizyphus vulgaris* Lam.), Aelwa (*Aloe barbadensis* Mill.) and Zafran (*Crocus sativa* L.) may be used to neutralize side effects (15-18).

#### 3.2.10.1 Therapeutic actions and uses of Tabasheer:

*Mufarrih-i-Qalb* (exhilarant), *Qabid* (astringent), *Mujaffif* (desiccant), and *Mubarrid Shaded* (powerful refrigerant) (15-18).

*Khafaqan* (palpitation), *Ghashi* (syncope), *Safrawi Qay'* (bilious vomiting), and *Jarayan* (spermatorrhoea) (15-18).

#### 3.2.10.3 Pharmacological properties:

Antibacterial activity (103), Anti-inflammatory and anti-ulcer effect (104), Anti-Infertility activity (105), Anti-diabetic activity (106-107).

## 3.3 DISCUSSION AND CONCLUSION

Present management for liver diseases especially for hypoalbuminemia is to provide albumin, amino acids, recombinant human growth hormone, to supplement the need and to enhance ability of the liver to synthesize albumin. However, this type of treatment is expensive and chances of infections exist there (108). In Unani Medicines the pathogenesis of anemia with hypoproteinaemia is clearly discussed in length. The main reason behind it is alteration of the *Mizāj* (temperament) and *Quwwat Mughayyira* (transformative faculty) of the liver leading to insufficiency of the liver. The treatment of this condition is to improve liver functions and detoxify it by hepatoprotective drugs for the production of healthy blood with all components, enzymes and hormones. The symptoms and signs of Unani Medicine (USM) in patients with AHP include puffiness of face, eyelids, upper arms, or whole body, lethargy, paleness, loss of appetite, gingivitis, constipation, alternate diarrhea, disturbed or deep sleep, psychogenic disorders (4).

QZ is a potent polyherbal Unani formulation that has been successfully used in the USM for generations to treat various liver diseases in general and anemia with hypoproteinaemia in particular. A number of studies have shown that the ingredients of QZ have significant hepatoprotective effect. The ingredients also shown anti-inflammatory, antioxidant, anticancer, and antihyperlipidemic effects which may have beneficial effects on overall immunity, and counter inflammation. Therefore, the long-term efficacy of QZ in the treatment of AHP is more significant,

and its long-term use may not produce any life-threatening adverse effect as all ingredients has been used in natural form without any processing. Despite being particularly efficient in the treatment of liver ailments, there is a dearth of scientific data regarding its effects. To confirm the therapeutic benefit of QZ, systematic, large-scale, randomized controlled trials are suggested. The results of the clinical trials will show how well QZ has worked overall in treating AHP. In order to support the use of QZ in the management of AHP, the mechanism of action of QZ may also be explored.

## 5. Conflicts of Interest

The authors declare no conflicts of interest.

## REFERENCES

1. Anonymous, Editorial, Hepatic insufficiency, British Medical Journal, London, 1955, pp. 1607
2. Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. *Hepatology*. 1994 Feb 1;19(2):518-33.
3. Wen J, Chen X, Wei S, Ma X, Zhao Y. Research progress and treatment status of liver cirrhosis with hypoproteinemia. *Evidence-based Complementary and Alternative Medicine*. 2022 Feb 24;2022.
4. Anonymous; National Formulary of Unani Medicine, Part. I Reprint Edn. Department of AYUSH, Ministry of Health & Family Welfare, Govt. of India, New Delhi, 2006, p. 46.
5. Khan HMA, *Rumuz-i-A 'zam*, CCRUM, New Delhi, 2006, Vol-II, 2, pp. 21.
6. Baghdadi, Ibn Hubal [d. 1213 AD], *Kitab al-Mukhtarat fi'l Tibb*, Vol. I-IV, CCRUM, New Delhi, pp. 286-287.
7. Ibn Sina, (1411AH), *Al-Qanun fi'l Tibb*, Urdu translation by Syed Gulam Hasnain Kanturi, Idara Kitabus Shifa, New Delhi, pp. 884-885.
8. Kabiruddin, HM, 1916. *Moalijat Sharah Asbab (Tarjuma-e-Kabir)*. Vol. II, Idara Kitabus Shifa, Delhi, 2009, pp. 560.
9. Khan MHA. Haziq, Manijir Hindustani Dawakhana Delhi March 1987, pp. 218-223
10. Tabri RAH. *Firdaus-ul- Hikmat*, Ejaz Publisher House, New Delhi; 2007, pp. 116-119.
11. Kantoori SGH. *Tarjuma Kamil us Sana*. Munshi Nawal Kishore. Lucknow. 1885, vol. 1 & 339, 517-521.
12. Razi, ABMZ, *Kitab al-Hawi fi'l Tibb*, CCRUM, New Delhi, 2010, Vol. VII, p. 99.
13. Nadkarni, KM. *Indian Materia Medica*, Bombay Popular Prakashan, Pvt. Ltd., Bombay, 2000, Vol.1. pp. 187; 1056; 1072; 403;1026; 313; 148; 582; 859;172

14. Khare CP. Indian Medicinal Plants, An illustrated Dictionary, Springer Springer-Verlag Berlin/Heidelberg, 2007, pp 88-89; 543-544; 555; 182, 181; 579-80; 146-147; 289-90; 441; 80-81
15. Ghani, N. Khazainul Advia. New Delhi, India: Idara Kitabul Shifa. 2011, pp. 758; 750; 1135; 1053; 1100; 932; 997; 1175; 1260; 1329; 395.
16. Kabir al-Din, HM [1894-1976 AD], Kitabul Adviya, (5<sup>th</sup> Edition), Vol. II, Makhzanul Mufradat, Daftar al-Masih, Bazar Nur al-Umara', Hyderabad Deccan, 1955, pp.206; 204; 326; 116; 264; 117; 342; 366; 266.
17. Arshi MMN, Mufradat-e-Arshi, Kutubkhana Arshi Dhanola, Pratap Press Lahore, 1929; p. 319; 318; 380; 375; 367; 364; 268; 389; 404; 245
18. Fazlullah M, Makhzanul Mufradat Maroofba Jamia ul Advia, Dar Matba Anwar Muhammad, Lucknow, 1877, p. 126; 125; 188; 172; 180; 157; 216; 231; 248; 53.
19. Sohni YR, Bhatt RM. Activity of a crude extract formulation in experimental hepatic amoebiasis and in immunomodulation studies. Journal of Ethnopharmacology. 1996 Nov 1;54(2-3):119-24.
20. Gilani AH, Janbaz KH. Prevention of acetaminophen-induced liver damage by Berberis aristata leaves. Biochemical Society transactions. 1992 Nov;20(4):347S.
21. Patel AM, Darade SS, Jain PG, Kandalkar AM. Formulation and evaluation of proprietary polyherbal formulation for their hepatoprotective activity. International Journal of Pharm Tech Research. 2010;2(1):305-9.
22. Joshi PV, Shirkhedkar AA, Prakash K, Maheshwari VL. Antidiarrheal activity, chemical and toxicity profile of Berberis aristata. Pharmaceutical Biology. 2011 Jan 1;49(1):94-100.
23. Sack RB, Froehlich JL. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infection and immunity. 1982 Feb;35(2):471-5.
24. Tripathi YB, Shukla SD. Berberis aristata inhibits PAF induced aggregation of rabbit platelets. Phytotherapy Research. 1996 Nov;10(7):628-30.
25. Ahmed KM, Khan M, Shivananda B. Cardiovascular diseases and role of medicinal plants as a re-emerging health aid. Pharmacognosy Reviews. 2009;3(5):8-14.
26. Gilani AH, Janbaz KH, Aziz N, Herzig MJ, Kazmi MM, Choudhary MI, Herzig JW. Possible mechanism of selective inotropic activity of the n-butanolic fraction from Berberis aristata fruit. General Pharmacology: The Vascular System. 1999 Nov 1;33(5):407-14.

27. Semwal BC, Shah K, Chauhan NS, Badhe R, Divakar K. Anti-diabetic activity of stem bark of *Berberis aristata* DC in alloxan induced diabetic rats. *Internet J Pharmacol*. 2008 Nov;6:1531-76.
28. Singh J, Kakkar P. Antihyperglycemic and antioxidant effect of *Berberis aristata* root extract and its role in regulating carbohydrate metabolism in diabetic rats. *Journal of ethnopharmacology*. 2009 May 4;123(1):22-6.
29. Upwar N, Patel R, Waseem N, Mahobia NK. Hypoglycemic effect of methanolic extract of *Berberis aristata* DC stem on normal and streptozotocin induced diabetic rats. *Int J Pharm Pharm Sci*. 2011;3(1):222-4.
30. Das S, Das MK, Mazumder PM, Das S, Basu SP. Cytotoxic activity of methanolic extract of *Berberis aristata* DC on colon cancer. *Global Journal of Pharmacology*. 2009 Mar;3(3):137-40.
31. Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. *Journal of Pharmacy and Pharmacology*. 2001 May;53(5):763-8.
32. Choi MS, Yuk DY, Oh JH, Jung HY, Han SB, Moon DC, Hong JT. Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis. *Anticancer research*. 2008 Nov 1;28(6A):3777-84.
33. Gupta SK, Agarwal R, Srivastava S, Agarwal P, Agrawal SS, Saxena R, Galpalli N. The anti-inflammatory effects of *Curcuma longa* and *Berberis aristata* in endotoxin-induced uveitis in rabbits. *Investigative ophthalmology & visual science*. 2008 Sep 1;49(9):4036-40.
34. Soffar SA, Metwali DM, Abdel-Aziz SS, El-Wakil HS, Saad GA. Evaluation of the effect of a plant alkaloid (berberine derived from *Berberis aristata*) on *Trichomonas vaginalis* in vitro. *Journal of the Egyptian Society of Parasitology*. 2001 Dec 1;31(3):893-904.
35. Mathur A, Singh R, Yousuf S, Bhardwaj A, Verma SK, Babu P, Gupta V, Prasad GB, Dua VK. Antifungal activity of some plant extracts against clinical pathogens. *Adv. Appl. Sci. Res*. 2011;2(2):260-4.
36. Kulkarni SK, Dhir A. On the mechanism of antidepressant-like action of berberine chloride. *European Journal of Pharmacology*. 2008 Jul 28;589(1-3):163-72.
37. Kulkarni SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2010 Mar;24(3):317-24.

38. Semwal RB, Semwal DK, Combrinck S, Viljoen A. Emodin - A natural anthraquinone derivative with diverse pharmacological activities. *Phytochemistry*. 2021 Oct;190:112854
39. Zhang WS, Li F, Bao JQ, Wang SC, Shang GW, Li JC, Wang CH. Regulative effects of aquaporin 4 expression by rhein in rhubarb to intestinal epithelial cell line LoVo. *Journal of Chinese medicinal materials*, 2008 May;31(5):702-6.
40. Rajkumar V, Guha G, Ashok Kumar R. Antioxidant and Anti-Cancer Potentials of *Rheum emodi* Rhizome Extracts. *Evid Based Complement Alternat Med*. 2011;2011:697986.
41. Ibrahim M, Khaja MN, Aara A, Khan AA, Habeeb MA, Devi YP, Narasu ML, Habibullah CM. Hepatoprotective activity of *Sapindus mukorossi* and *Rheum emodi* extracts: in vitro and in vivo studies. *World J Gastroenterol*. 2008 Apr 28;14(16):2566-71.
42. Dileep Kumar G, Siva B, Ashwini K, Vinod Kumar J, Ramalingam V, Sai Balaji A, Suresh Babu K. Design, synthesis, cytotoxic, and anti-inflammatory activities of some novel analogues of aloe-emodin isolated from the rhizomes of *Rheum emodi*. *Nat Prod Res*. 2023 May;37(9):1511-1517.
43. Arvindekar A, More T, Payghan PV, Laddha K, Ghoshal N, Arvindekar A. Evaluation of anti-diabetic and alpha glucosidase inhibitory action of anthraquinones from *Rheum emodi*. *Food Funct*. 2015 Aug;6(8):2693-700.
44. Pattanittum P, Kunyanone N, Brown J, Sangkomkarnhang US, Barnes J, Seyfoddin V, Marjoribanks J. Dietary supplements for dysmenorrhoea. *Cochrane Database Syst Rev*. 2016 Mar 22;3(3):CD002124
45. Zu Y, Yu H, Liang L, Fu Y, Efferth T, Liu X, Wu N. Activities of ten essential oils towards *Propionibacterium acnes* and PC-3, A-549 and MCF-7 cancer cells. *Molecules*. 2010 Apr 30;15(5):3200-10.
46. Shokouhinejad N, Emaneini M, Aligholi M, Jabalameli F. Antimicrobial effect of *Rosa damascena* extract on selected endodontic pathogens. *Journal of the California Dental Association*. 2010 Feb 1;38(2):123-6.
47. Mahmood N, Piacente S, Pizza C, Burke A, Khan AI, Hay AJ. The anti-HIV activity and mechanisms of action of pure compounds isolated from *Rosa damascena*. *Biochemical and biophysical research communications*. 1996 Dec 4;229(1):73-9.
48. Zaidi SF, Muhammad JS, Shahryar S, Usmanghani K, Gilani AH, Jafri W, Sugiyama T. Anti-inflammatory and cytoprotective effects of selected Pakistani medicinal plants in *Helicobacter pylori*-infected gastric epithelial cells. *Journal of Ethnopharmacology*. 2012 May 7;141(1):403-10.

49. Moein S, Moein M, Khoshnoud MJ, Kalanteri T. In vitro antioxidant properties evaluation of 10 Iranian medicinal plants by different methods. *Iranian Red Crescent Medical Journal*. 2012 Dec;14(12):771-775.
50. Artun T, Karagoz A, Ozcan G, Melikoglu G, Anil S, Kultur S, Sutlupinar N. In vitro anticancer and cytotoxic activities of some plant extracts on HeLa and Vero cell lines. *Journal of BUON: official journal of the Balkan Union of Oncology*. 2016 May 1;21(3):720-5.
51. Mizuno D, Konoha-Mizuno K, Mori M, Yamazaki K, Haneda T, Koyama H, Kawahara M. An In Vitro System Comprising Immortalized Hypothalamic Neuronal Cells (GT1–7 Cells) for Evaluation of the Neuroendocrine Effects of Essential Oils. *Evidence-Based Complementary and Alternative Medicine*. 2015 Jan 1;2015.
52. Gholamhoseinian A, Fallah H. Inhibitory effect of methanol extract of *Rosa damascena* Mill. flowers on  $\alpha$ -glucosidase activity and postprandial hyperglycemia in normal and diabetic rats. *Phytomedicine* 2009 Oct 1;16(10):935-41.
53. Nema NK, Maity N, Sarkar B, Mukherjee PK. *Cucumis sativus* fruit-potential antioxidant, anti-hyaluronidase, and anti-elastase agent. *Archives of dermatological research*. 2011 May;303:247-52.
54. Sotiroudis G, Melliou E, Sotiroudis TG, Chinou I. Chemical analysis, antioxidant and antimicrobial activity of three Greek cucumber (*Cucumis sativus*) cultivars. *Journal of Food Biochemistry*. 2010 Mar;34:61-78.
55. Maheshwar GH, Patil BS, Dhumal P. Comparative sun protection factor determination of fresh fruits extract of Cucumber vs marketed cosmetic formulation. *Research Journal of Pharmaceutical Biological and Chemical Sciences*. 2010;1(3):55-9.
56. Kai H, Baba M, Okuyama T. Inhibitory effect of *Cucumis sativus* on melanin production in melanoma B16 cells by downregulation of tyrosinase expression. *Planta medica*. 2008 Nov 13:1785-8.
57. Dixit Y, Kar A. Protective role of three vegetable peels in alloxan induced diabetes mellitus in male mice. *Plant Foods for Human Nutrition*. 2010 Sep;65:284-9.
58. Chandrasekar B, Mukherjee B, Mukherjee SK. Blood sugar lowering potentiality of selected Cucurbitaceae plants of Indian origin. *The Indian journal of medical research*. 1989 Aug 1;90:300-5.
59. Sudheesh S, Vijayalakshmi N. Lipid-lowering action of pectin from *Cucumis sativus*. *Food chemistry*. 1999;67(3):281-6.
60. Gopalakrishnan S, Kalaiarasi T. Hepatoprotective activity of the fruits of *Cucumis sativus* (L.). *International Journal of Pharmaceutical Sciences Review and Research*. 2013;20(2):229-34.

61. Tuama AA, Mohammed AA. Phytochemical screening and in vitro antibacterial and anticancer activities of the aqueous extract of *Cucumis sativus*. Saudi journal of biological sciences. 2019 Mar 1;26(3):600-4.
62. Kulkarni CR, Joglekar MM, Patil SB, Arvindekar AU. Antihyperglycemic and antihyperlipidemic effect of *Santalum album* in streptozotocin induced diabetic rats. Pharmaceutical Biology. 2012 Mar 1;50(3):360-5.
63. Kim TH, Hatano T, Okamoto K, Yoshida T, Kanzaki H, Arita M, Ito H. Antifungal and ichthyotoxic sesquiterpenoids from *Santalum album* heartwood. Molecules. 2017 Jul 8;22(7):1139.
64. Misra BB, Dey S. Comparative phytochemical analysis and antibacterial efficacy of in vitro and in vivo extracts from East Indian sandalwood tree (*Santalum album* L.). Letters in applied microbiology. 2012 Dec 1;55(6):476-86.
65. Scartezzini P, Speroni E. Review on some plants of Indian traditional medicine with antioxidant activity. Journal of ethnopharmacology. 2000 Jul 1;71(1-2):23-43.
66. Kaur M, Agarwal C, Singh RP, Guan X, Dwivedi C, Agarwal R. Skin cancer chemopreventive agent,  $\alpha$ -santalol, induces apoptotic death of human epidermoid carcinoma A431 cells via caspase activation together with dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis. 2005 Feb 1;26(2):369-80.
67. Rub RA, Sasikumar S. Antimicrobial screening of *Cichorium intybus* seed extracts. Arabian Journal of Chemistry. 2016 Nov 1;9:S1569-73.
68. Nandagopal S, Kumari BR. Phytochemical and antibacterial studies of Chicory (*Cichorium intybus* L.)-A multipurpose medicinal plant. Advances in Biological Research. 2007 Jan;1(1-2):17-21.
69. Marley CL, Cook R, Keatinge R, Barrett J, Lampkin NH. The effect of birdsfoot trefoil (*Lotus corniculatus*) and chicory (*Cichorium intybus*) on parasite intensities and performance of lambs naturally infected with helminth parasites. Veterinary parasitology. 2003 Feb 28;112(1-2):147-55.
70. Foster JG, Cassida KA, Turner KE. In vitro analysis of the anthelmintic activity of forage chicory (*Cichorium intybus* L.) sesquiterpene lactones against a predominantly *Haemonchus contortus* egg population. Veterinary Parasitology. 2011 Aug 25;180(3-4):298-306.
71. Bischoff TA, Kelley CJ, Karchesy Y, Laurantos M, Nguyen-Dinh P, Arefi AG. Antimalarial activity of lactucin and lactucopicrin: sesquiterpene lactones isolated from *Cichorium intybus* L. Journal of ethnopharmacology. 2004 Dec 1;95(2-3):455-7.



72. Gilani AH, Janbaz KH. Evaluation of the liver protective potential of *Cichorium intybus* seed extract on Acetaminophen and CCl<sub>4</sub>-induced damage. *Phytomedicine*. 1994 Dec 1;1(3):193-7.
73. Zafar R, Ali SM. Anti-hepatotoxic effects of root and root callus extracts of *Cichorium intybus* L. *Journal of Ethnopharmacology*. 1998 Dec 1;63(3):227-31.
74. Pushparaj PN, Low HK, Manikandan J, Tan BK, Tan CH. Anti-diabetic effects of *Cichorium intybus* in streptozotocin-induced diabetic rats. *Journal of ethnopharmacology*. 2007 May 4;111(2):430-4.
75. Hardeep FM, Pandey DK. Anti-diabetic activity of methanolic extract of chicory roots in streptozocin induced diabetic rats. *International Journal of Pharmacy*. 2013;3(1):211-6.
76. Gurbuz İ, Ustun O, Yeşilada E, Sezik E, Akyurek N. In vivo gastroprotective effects of five Turkish folk remedies against ethanol-induced lesions. *Journal of Ethnopharmacology*. 2002 Dec 1;83(3):241-4.
77. Wesołowska A, Nikiforuk A, Michalska K, Kisiel W, Chojnacka-Wójcik E. Analgesic and sedative activities of lactucin and some lactucin-like guaianolides in mice. *Journal of ethnopharmacology*. 2006 Sep 19;107(2):254-8.
78. Papetti A, Daglia M, Grisoli P, Dacarro C, Gregotti C, Gazzani G. Anti-and pro-oxidant activity of *Cichorium* genus vegetables and effect of thermal treatment in biological systems. *Food Chemistry*. 2006 Jul 1;97(1):157-65.
79. Hazra B, Sarkar R, Bhattacharyya S, Roy P. Tumour inhibitory activity of chicory root extract against Ehrlich ascites carcinoma in mice. *Fitoterapia*. 2002 Dec 1;73(7-8):730-3.
80. Ali Mohammad, *Text of Pharmacognosy*, CBS Publishers & Distributers Pvt. Ltd. New Delhi, second edition, 2000 pp.398-400.
81. Poorassar A, Ardekani MR, Hajhashemi V, Rahimi R, Ardakani MM, Aghayeghazvini M. Antiobesity effects of seedlac and shellac in rats fed with a high-fat diet. *Research in Pharmaceutical Sciences*. 2020 Feb;15(1):57.
82. Jahangir U, Khan AA, Kapoor P, Jalees F, Urooj S. Evaluation of a classical unani pharmacopeial formulation Safoof-e-Muhazzil in hyperlipidemia: A randomized, standard controlled clinical study. *J Pharm Bioallied Sci*. 2014 Jul;6(3):167-79
83. Aisha P. *Evaluation of Luk for its antifertility activity in rat model* (Doctoral dissertation, Dissertation. Rajiv Gandhi University of Health Sciences (RGUHS) in Ilmul Advia (Pharmacology). Bangalore, Karnataka, India).

84. Ghufran A, Laique A, Khan NA. The effect of *Luk Magsool*(processed Lac) on diet induced hyperlipidemia in albino rats. *Hippocratic Journal of Unani Medicine* 2011; 6(2): 155-165.
85. Varsha S, Agrawal RC, Sonam P. Phytochemical screening and determination of anti-bacterial and anti-oxidant potential of *Glycyrrhiza glabra* root extracts. *Journal of environmental Research and Development*. 2013 Apr 1;7(4A):1552.
86. Biondi DM, Rocco C, Ruberto G. New Dihydrostilbene Derivatives from the Leaves of *Glycyrrhiza glabra* and Evaluation of Their Antioxidant Activity. *Journal of natural products*. 2003 Apr 25;66(4):477-80.
87. Rackova L, Jancinova V, Petrikova M, Drabikova K, Nosal' R, Stefek M, Kost'alova D, Prónayova N, Kovacova M. Mechanism of anti-inflammatory action of liquorice extract and glycyrrhizin. *Natural product research*. 2007 Dec 1;21(14):1234-41.
88. Damle M. *Glycyrrhiza glabra* (Liquorice)-a potent medicinal herb. *International journal of herbal medicine*. 2014;2(2):132-6.
89. Bardhan KD, Cumberland DC, Dixon RA, Holdsworth CD. Clinical trial of deglycyrrhizised liquorice in gastric ulcer. *Gut*. 1978 Sep 1;19(9):779-82.
90. Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Antimicrobial activity of licorice flavonoids against methicillin-resistant *Staphylococcus aureus*. *Fitoterapia*. 2002 Oct 1;73(6):536-9.
91. Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. *Acta pharmaceuticasinica B*. 2015 Jul 1;5(4):310-5.
92. Soufy H, Yassein S, Ahmed AR, Khodier MH, Kutkat MA, Nasr SM, Okda FA. Antiviral and immune stimulant activities of glycyrrhizin against duck hepatitis virus. *African Journal of Traditional, Complementary and Alternative Medicines*. 2012;9(3):389-95.
93. Sharma V, Agrawal RC. In vivo antioxidant and hepatoprotective potential of *Glycyrrhiza glabra* extract on carbon tetra chloride (CCl<sub>4</sub>) induced oxidative-stress mediated hepatotoxicity. *Int J Res Med Sci*. 2014 Jan;2(1):314-20.
94. Lee CS, Kim YJ, Lee MS, Han ES, Lee SJ. 18 $\beta$ -Glycyrrhetic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity. *Life sciences*. 2008 Sep 26;83(13-14):481-9.
95. Chakravarthi KK, Avadhani R. Beneficial effect of aqueous root extract of *Glycyrrhiza glabra* on learning and memory using different behavioral models: An experimental study. *Journal of natural science, biology, and medicine*. 2013 Jul;4(2):420.

96. Dhingra D, Sharma A. Antidepressant-like activity of *Glycyrrhiza glabra* L. in mouse models of immobility tests. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2006 May 1;30(3):449-54.
97. Rafiq al-Din, Hakim Muhammad, Kanzul Adviya Mufrada, University Publication Unit, Sarfraz House, AMU Aligarh 1985, pp. 592
98. Cudalbeanu M, Furdui B, Carac G, Barbu V, Iancu AV, Marques F, et.al. Antifungal, antitumoral and antioxidant potential of the danube delta *Nymphaea alba* extracts. *Antibiotics*. 2019 Dec 21;9(1):7.
99. Nengroo ZR, Rauf A. Fatty Acid Composition, Functional Group Analysis and Antioxidant Activity of *Nymphaea alba* and *Lupinus polyphyllus* Seed Extracts. *J Oleo Sci*. 2020;69(4):317-326.
100. Bakr RO, El-Naa MM, Zaghloul SS, Omar MM. Profile of bioactive compounds in *Nymphaea alba* L. leaves growing in Egypt: hepatoprotective, antioxidant and anti-inflammatory activity. *BMC Complement Altern Med*. 2017 Jan 17;17(1):52
101. Rehman S, Ashfaq UA, Ijaz B, Riazuddin S. Anti-hepatitis C virus activity and synergistic effect of *Nymphaea alba* extracts and bioactive constituents in liver infected cells. *MicrobPathog*. 2018 Aug;121:198-209
102. N'guessan BB, Asiamah AD, Arthur NK, Frimpong-Manso S, Amoateng P, Amponsah SK, et.al. Ethanolic extract of *Nymphaea lotus* L.(*Nymphaeaceae*) leaves exhibits in vitro antioxidant, in vivo anti-inflammatory and cytotoxic activities on Jurkat and MCF-7 cancer cell lines. *BMC Complementary Medicine and Therapies*. 2021 Dec;21(1):1-3.
103. Aakruti AK, Swati RD, Vilasrao JK. Overview of Indian medicinal tree: *Bambusa bambos* (Druce). *Int. Res. J. Pharm*. 2013;4:52-6.
104. Muniappan M, Sundararaj T. Antiinflammatory and antiulcer activities of *Bambusa arundinacea*. *Journal of Ethnopharmacology*. 2003 Oct 1;88(2-3):161-7.
105. Jivani NP. Phytopharmacological properties of *Bambusa arundinacea* as a potential medicinal tree: An overview. *Journal of Applied Pharmaceutical Science*. 2011 Dec 30(Issue):27-31.
106. Ali W, Shaikh H, Ansari A, Khanam S. Standardization of Unani Antidiabetic Tablet - Qurse Tabasheer. *Pharmacognosy Res*. 2016 Apr-Jun;8(2):147-52.
107. Ahmed D, Sharma M, Mukerjee A, Ramteke PW, Kumar V. Improved glycemic control, pancreas protective and hepatoprotective effect by traditional poly-herbal formulation "Qurs Tabasheer" in streptozotocin induced diabetic rats. *BMC Complement Altern Med*. 2013 Jan 10;13:10.

108. Wen J, Chen X, Wei S, Ma X, Zhao Y. Research progress and treatment status of liver cirrhosis with hypoproteinemia. Evidence-based Complementary and Alternative Medicine. 2022 Feb 24;2022.